Gain Therapeutics Presents GT-02287 Biomarker Signals and Aims for Phase 2 Start in Q3 at Roth Conference.

Gain Therapeutics is developing oral small-molecule drugs for neurodegenerative diseases, focusing on Parkinson's disease. CEO Gene Mack discussed the company's drug-discovery platform and early clinical findings for lead candidate GT-02287. Mack emphasized the importance of addressing disease biology beyond symptomatic relief, aiming to create a "backbone of therapy" that could delay the need for increasing doses of standard treatments.